Argus
•
Sep 02, 2026
XNCR: Lowering target price to $29.00
Summary
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Biogen Inc.
Sep 03, 2026
•
BIIB
PTCT: Lowering target price to $67.00
Sep 02, 2026
•
PTCT
PTGX: Lowering target price to $154.00
Sep 02, 2026
•
PTGX
RCUS: Lowering target price to $31.00
Sep 02, 2026
•
RCUS
Technical Assessment: Bullish in the Intermediate-Term
Aug 31, 2026
•
TWLO, MRK
